Order Article Reprints

Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, Laureys G, Brock P, Michon JM, Owens C, et al. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers. 2020; 12(2):309. https://doi.org/10.3390/cancers12020309

Ladenstein, Ruth, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Shifra Ash, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, and et al. 2020. "Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)" Cancers 12, no. 2: 309. https://doi.org/10.3390/cancers12020309

Ladenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Ash, S., Laureys, G., Brock, P., Michon, J. M., Owens, C., Trahair, T., Chi Fung Chan, G., Ruud, E., Schroeder, H., Beck-Popovic, M., Schreier, G., Loibner, H., Ambros, P., Holmes, K., ... Lode, H. N. (2020). Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers, 12(2), 309. https://doi.org/10.3390/cancers12020309